Pivotal bioVenture Partners Investment Advisor LLC Acquires 563,078 Shares of Oculis Holding AG $OCS

Key Points

• Pivotal bioVenture Partners Investment Advisor LLC increased its stake in Oculis Holding AG by 32.4%, owning approximately 35.4% of the company with a value of around $43.78 million as of the last quarter.
• Oculis reported a negative earnings per share of ($0.59) for the most recent quarter, falling short of expectations, although the revenue of $0.25 million surpassed analyst predictions.
• Analysts show a positive outlook for Oculis, with a consensus rating of "Buy" and an average target price of about $35.67.

Pivotal bioVenture Partners Investment Advisor LLC grew its position in Oculis Holding AG (NASDAQ:OCS - Free Report) by 32.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,300,774 shares of the company's stock after acquiring an additional 563,078 shares during the period. Oculis accounts for approximately 35.4% of Pivotal bioVenture Partners Investment Advisor LLC's investment portfolio, making the stock its biggest position. Pivotal bioVenture Partners Investment Advisor LLC owned 5.27% of Oculis worth $43,784,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bellevue Group AG acquired a new position in Oculis during the 4th quarter valued at about $170,000. XTX Topco Ltd bought a new position in shares of Oculis in the fourth quarter worth $225,000. Kestra Private Wealth Services LLC purchased a new position in Oculis in the first quarter worth $234,000. Geode Capital Management LLC boosted its position in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after buying an additional 1,800 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in shares of Oculis during the fourth quarter worth about $389,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on OCS shares. HC Wainwright raised their target price on shares of Oculis from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, August 22nd. Needham & Company LLC started coverage on shares of Oculis in a research note on Wednesday. They set a "buy" rating and a $36.00 target price on the stock. Finally, Chardan Capital lifted their price target on shares of Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a report on Friday, May 9th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $35.75.

Oculis Trading Down 5.7%

Shares of OCS traded down $0.98 during trading on Thursday, reaching $16.35. 27,275 shares of the company traded hands, compared to its average volume of 43,812. Oculis Holding AG has a twelve month low of $11.56 and a twelve month high of $23.08. The stock has a market cap of $713.84 million, a PE ratio of -6.12 and a beta of 0.27. The stock has a 50-day simple moving average of $18.27 and a 200-day simple moving average of $18.61. The company has a quick ratio of 4.55, a current ratio of 4.55 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The business had revenue of $0.25 million during the quarter, compared to analysts' expectations of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. On average, analysts anticipate that Oculis Holding AG will post -2.09 earnings per share for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.